All News Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
19.83 ^USD	-8.02%		-2.27%	-12.37%

12/04	Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	MT
04/04	Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aerovate Therapeutics : May 2024 Corporate Presentation	02/05	PU
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	12/04	MT
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	04/04	MT
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference	27/03	AQ
Aerovate Therapeutics Q4 Loss Widens	26/03	MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03	CI
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights	26/03	AQ
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing	21/03	MT
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair	06/03	AQ
Aerovate Therapeutics, Inc. Announces Board Changes	06/03	CI
Aerovate Therapeutics : March 2024 Corporate Presentation	01/03	PU
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing	08/12	MT
Aerovate Therapeutics : December 2023 Corporate Presentation	01/12	PU
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing	30/11	MT
Aerovate Therapeutics Completes Enrollment in Phase 2b Portion of Trial for Treatment of Pulmonary Arterial Hypertension	21/11	MT
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension	21/11	CI
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	21/11	AQ
Aerovate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights	13/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

All News

Filters